A head‐to‐head comparison of risankizumab and ixekizumab for genital psoriasis: a real‐life, 24‐week, prospective study.

2021 ◽  
Author(s):  
E Sotiriou ◽  
K Bakirtzi ◽  
I Papadimitriou ◽  
A Tsentemeidou ◽  
P Eftychidou ◽  
...  
Keyword(s):  
Prospective Study ◽  
Real Life ◽  
Genital Psoriasis

Incidence and risk factors for dupilumab associated ocular adverse events: a real‐life prospective study

2020 ◽  
Author(s):  
A.T. Touhouche ◽  
M. Cassagne ◽  
E. Bérard ◽  
F. Giordano‐Labadie ◽  
A. Didier ◽  
...  
Keyword(s):  
Risk Factors ◽  
Adverse Events ◽  
Prospective Study ◽  
Real Life

Management of Uncomplicated Acute Appendicitis as Day Case Surgery: Can Outcomes of a Prospective Study Be Reproduced in Real Life?

2019 ◽  
Vol 229 (3) ◽  
pp. 277-285 ◽  
Author(s):  
Charles Sabbagh ◽  
Loréna Masseline ◽  
Gérard Grelpois ◽  
Alexandre Ntouba ◽  
Jeanne Dembinski ◽  
...  
Keyword(s):  
Acute Appendicitis ◽  
Prospective Study ◽  
Real Life ◽  
Day Case ◽  
Day Case Surgery ◽  
Case Surgery ◽  
Uncomplicated Acute Appendicitis ◽  
A Prospective Study

PD07-02 PCA3 IN PROSTATE CANCER RISK ASSESSMENT: HOW DOES IT HELP IN REAL LIFE? RESULT OF A 5–YEAR PROSPECTIVE STUDY

2017 ◽  
Vol 197 (4S) ◽  
Author(s):  
Marine Lesourd ◽  
Jean Baptiste Beauval ◽  
Benjamin Pradere ◽  
Daniel Portalez ◽  
Xavier Gamé ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Risk Assessment ◽  
Cancer Risk ◽  
Prospective Study ◽  
Real Life ◽  
Prostate Cancer Risk ◽  
Cancer Risk Assessment

scholarly journals Duration of the efficacy of omalizumab after treatment discontinuation in ‘real life’ severe asthma

Thorax ◽  
2017 ◽  
Vol 73 (8) ◽  
pp. 782-784 ◽  
Author(s):  
Maria del Carmen Vennera ◽  
Carlos Sabadell ◽  
Cesar Picado
Keyword(s):  
Prospective Study ◽  
Asthma Control ◽  
Severe Asthma ◽  
Asthma Exacerbation ◽  
Real Life ◽  
First Year ◽  
Severe Asthma Exacerbation ◽  
Optimal Duration ◽  
Open Prospective Study

Efficacy of omalizumab in severe asthma is well documented; however, the optimal duration of the treatment remains unclear. In an open prospective study, we sought to assess the persistence of response in subjects withdrawing from omalizumab treatment. We evaluated 49 patients who voluntarily accepted to discontinue omalizumab treatment after 6 years of therapy. Asthma relapse was defined as any severe asthma exacerbation associated with loss of asthma control. Twelve patients relapsed in the first year of follow-up, and 7 within 13 and 48 months. These results suggest that the effects of 6 years of omalizumab may persist after discontinuation of therapy in 60% of patients for at least 4 years.

scholarly journals An International Multicenter Real-Life Prospective Study of Electronic Chromoendoscopy Score PICaSSO in Ulcerative Colitis

2021 ◽  
Author(s):  
Marietta Iacucci ◽  
Samuel C.L. Smith ◽  
Alina Bazarova ◽  
Uday N. Shivaji ◽  
Pradeep Bhandari ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Prospective Study ◽  
Real Life ◽  
International Multicenter
Sign in / Sign up

Export Citation Format

Share Document